MAP2K7 and plasma cell myeloma: Here, we report the case of a patient with triple‐class refractory myeloma harboring BRAF mutation that achieved clinical response to dual BRAF and MEK inhibition but experienced early disease progression related to a clonal evolution involving RAS.